Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUL-042 for rhinovirus-induced symptoms in smokers with GOLD stage 0 COPD
2018-002806-30Phase 2Unknown
- Sponsor
- Pulmotect
- Start
- Sep 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, double-blind trial of PUL-042 in chronic obstructive pulmonary disease (COPD) and rhinoviral infection (2 arms), sponsored by Pulmotect. Primary endpoint: Peak lower respiratory symptom score. Status: unknown.
02
Drugs
PUL-042
03
Conditions
chronic obstructive pulmonary disease (COPD)rhinoviral infection
Beyond the preview
Go deeper on 2018-002806-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002806-30.